Powell speech takes center stage in Tuesday’s economic events
MALVERN, Pa. - TELA Bio, Inc. (NASDAQ:TELA), a medical technology company focused on soft-tissue reconstruction solutions, announced Thursday the appointment of Betty Jo Rocchio to its Board of Directors, while longtime board member Lisa Colleran has stepped down after five years of service. The company, which has demonstrated strong revenue growth of 16.34% over the last twelve months, maintains a healthy liquidity position with a current ratio of 3.19, according to InvestingPro data.
Rocchio, currently Executive Vice President and Chief Nurse Executive at Advocate Health, brings significant healthcare leadership experience to the board. She leads more than 42,000 nurses across a six-state healthcare system and has been recognized as one of Modern Healthcare’s 50 Most Influential Clinical Executives.
Prior to her role at Advocate Health, Rocchio served in leadership positions at Mercy and Mount Carmel Health System. She holds a Doctor of Nursing Practice from The Ohio State University and certifications in Executive Nurse Practice and Evidence-Based Practice.
"Her deep expertise in the group purchasing organization space and her proven ability to align clinical priorities with supply-chain strategy will be critical as we continue to drive value for our customers and shareholders," said Antony Koblish, Co-founder and Chief Executive Officer of TELA Bio, in a press release statement. While analysts have set price targets ranging from $2 to $7, InvestingPro analysis indicates the stock is currently trading below its Fair Value, with three analysts recently revising their earnings expectations downward for the upcoming period.
Colleran, who joined the board in 2020, is the CEO of IC Surgical and former CEO of LifeCell Corporation. During her tenure, she provided commercial expertise as the company expanded its portfolio and commercial presence.
TELA Bio develops technologies for soft-tissue reconstruction that aim to preserve and restore patient anatomy while minimizing long-term exposure to permanent synthetic materials. For a deeper understanding of TELA Bio’s financial health, growth prospects, and detailed analyst coverage, investors can access the comprehensive Pro Research Report, available exclusively on InvestingPro, which covers over 1,400 US stocks with expert analysis and actionable insights.
In other recent news, Tela Bio Inc. reported its Q2 2025 earnings, which showed a shortfall in both earnings per share (EPS) and revenue forecasts. The company reported an EPS of -$0.22, missing the expected -$0.18. Additionally, revenue was reported at $20.2 million, falling short of the anticipated $20.67 million. Despite these misses, the stock experienced a notable rise in aftermarket trading, indicating investor confidence. Analysts have pointed to strong product performance and positive growth prospects as potential reasons for this optimism. These recent developments are crucial for investors assessing Tela Bio’s financial health and future outlook. The company’s performance and market reaction highlight the importance of understanding both earnings results and market sentiment.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.